Thursday, April 16, 2009

Psipax




Psipax may be available in the countries listed below.


Ingredient matches for Psipax



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Psipax in the following countries:


  • Portugal

International Drug Name Search

Sunday, April 12, 2009

Vyvanse


Vyvanse is a brand name of lisdexamfetamine, approved by the FDA in the following formulation(s):


VYVANSE (lisdexamfetamine dimesylate - capsule; oral)



  • Manufacturer: SHIRE DEVELOPMENT

    Approval date: February 23, 2007

    Strength(s): 30MG, 50MG, 70MG [RLD]


  • Manufacturer: SHIRE DEVELOPMENT

    Approval date: December 10, 2007

    Strength(s): 20MG, 40MG, 60MG

Has a generic version of Vyvanse been approved?


No. There is currently no therapeutically equivalent version of Vyvanse available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyvanse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Abuse-resistant amphetamine compounds
    Patent 7,105,486
    Issued: September 12, 2006
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas
    Assignee(s): New River Pharmaceuticals Inc.
    The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)


    • June 29, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)




  • Abuse resistant lysine amphetamine compounds
    Patent 7,223,735
    Issued: May 29, 2007
    Inventor(s): Mickle; Travis & Krishnan; Suma & Moncrief; James Scott & Lauderback; Christopher & Bishop; Barney & Oberlender; Rob & Piccariello; Thomas
    Assignee(s): New River Pharmaceuticals Inc.
    The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,655,630
    Issued: February 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug substance




  • Abuse-resistant amphetamine prodrugs
    Patent 7,659,253
    Issued: February 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,659,254
    Issued: February 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS




  • Abuse resistant lysine amphetamine compounds
    Patent 7,662,787
    Issued: February 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug substance




  • Abuse-resistant amphetamine prodrugs
    Patent 7,662,788
    Issued: February 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,671,030
    Issued: March 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,671,031
    Issued: March 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 28, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,674,774
    Issued: March 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 18, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,678,770
    Issued: March 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 25, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,678,771
    Issued: March 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 25, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,687,466
    Issued: March 30, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,687,467
    Issued: March 30, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • April 8, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,700,561
    Issued: April 20, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,713,936
    Issued: May 11, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,718,619
    Issued: May 18, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,723,305
    Issued: May 25, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 23, 2011 - NEW PATIENT POPULATION

    • February 23, 2012 - NEW CHEMICAL ENTITY

    • April 5, 2013 - LABELING REVISIONS RELATED TO CLINICAL STUDIES

    • November 10, 2013 - NEW PATIENT POPULATION

    • January 31, 2015 - MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

See also...

  • Vyvanse Consumer Information (Drugs.com)
  • Vyvanse Consumer Information (Wolters Kluwer)
  • Vyvanse Consumer Information (Cerner Multum)
  • Vyvanse Advanced Consumer Information (Micromedex)
  • Vyvanse AHFS DI Monographs (ASHP)
  • Lisdexamfetamine Consumer Information (Wolters Kluwer)
  • Lisdexamfetamine Consumer Information (Cerner Multum)
  • Lisdexamfetamine dimesylate Advanced Consumer Information (Micromedex)
  • Lisdexamfetamine Dimesylate AHFS DI Monographs (ASHP)

Saturday, April 11, 2009

Tetragen




Tetragen may be available in the countries listed below.


Ingredient matches for Tetragen



Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Tetragen in the following countries:


  • Bangladesh

International Drug Name Search

Tuesday, April 7, 2009

Bromhist-DM


Generic Name: brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine (brom fen EER a meen, DEX tro me THOR fan, gwye FEN e sin, SOO doe ee FED rin)

Brand Names: Bromhist-DM, Histacol DM Pediatric Syrup, Pediahist DM Syrup


What is Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.


Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex.


Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine is used to treat sneezing, runny or stuffy nose, cough, chest congestion, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold.


Dextromethorphan will not treat a cough that is caused by smoking, asthma, or emphysema.

Brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Ask a doctor or pharmacist before using any other cough, cold, allergy, or sleep medication. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine, decongestant, expectorant, or cough suppressant. This medication impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body. Drinking alcohol can increase certain side effects of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine. Dextromethorphan will not treat a cough that is caused by smoking, asthma, or emphysema.

What should I discuss with my healthcare provider before taking Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:


  • kidney disease;


  • diabetes;




  • glaucoma;




  • heart disease or high blood pressure;




  • diabetes;




  • a thyroid disorder;




  • emphysema or chronic bronchitis;




  • an enlarged prostate; or




  • problems with urination.




This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially sweetened liquid cough or cold medicine may contain phenylalanine. If you have phenylketonuria (PKU), check the medication label to see if the product contains phenylalanine.


How should I take Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Take this medicine with a full glass of water. Do not crush, chew, or break an extended-release tablet. Swallow the pill whole. Breaking or opening the pill would cause too much of the drug to be released at one time.

Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash.

If you need surgery, tell the surgeon ahead of time if you have taken a cold medicine within the past few days.


This medication can cause you to have unusual results with allergy skin tests. Tell any doctor who treats you that you are taking an antihistamine.


Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Since brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include feeling restless or nervous, nausea, vomiting, stomach pain, dizziness, drowsiness, dry mouth, warmth or tingly feeling, or seizure (convulsions).


What should I avoid while taking Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Ask a doctor or pharmacist before using any other cough, cold, allergy, or sleep medication. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine, decongestant, expectorant, or cough suppressant. This medication impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine.

Avoid taking diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • slow, shallow breathing;




  • confusion, hallucinations, unusual thoughts or behavior;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure);




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms; or




  • urinating less than usual or not at all.



Less serious side effects may include:



  • dry mouth;




  • nausea, stomach pain, constipation, mild loss of appetite, upset stomach;




  • blurred vision;




  • warmth, tingling, or redness under your skin;




  • sleep problems (insomnia);




  • feeling restless or excited (especially in children);




  • skin rash or itching;




  • dizziness, drowsiness, or headache;




  • problems with memory or concentration; or




  • ringing in your ears.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Before taking this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by brompheniramine, dextromethorphan, or guaifenesin.

Tell your doctor about all other medications you use, especially:



  • a diuretic (water pill), or blood pressure medicine;




  • medication to treat irritable bowel syndrome;




  • bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol), darifenacin (Enablex), or tolterodine (Detrol);




  • aspirin or salicylates (such as Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal, and others);




  • a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol (Blocadren), and others; or




  • antidepressants such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.



This list is not complete and other drugs may interact with brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Bromhist-DM resources


  • Bromhist-DM Side Effects (in more detail)
  • Bromhist-DM Use in Pregnancy & Breastfeeding
  • Bromhist-DM Drug Interactions
  • Bromhist-DM Support Group
  • 0 Reviews for Bromhist-DM - Add your own review/rating


  • Bromhist-DM Syrup MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Bromhist-DM with other medications


  • Cold Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine.

See also: Bromhist-DM side effects (in more detail)


Saturday, April 4, 2009

Dutoprol


Dutoprol is a brand name of hydrochlorothiazide/metoprolol, approved by the FDA in the following formulation(s):


DUTOPROL (hydrochlorothiazide; metoprolol succinate - tablet, extended release; oral)



  • Manufacturer: ASTRAZENECA

    Approval date: August 28, 2006

    Strength(s): 12.5MG;EQ 100MG TARTRATE, 12.5MG;EQ 25MG TARTRATE, 12.5MG;EQ 50MG TARTRATE

Has a generic version of Dutoprol been approved?


No. There is currently no therapeutically equivalent version of Dutoprol available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dutoprol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Dutoprol.

See also...

  • Metoprolol/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide and metoprolol Consumer Information (Cerner Multum)
  • Metoprolol and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Lasix Retard




Lasix Retard may be available in the countries listed below.


Ingredient matches for Lasix Retard



Furosemide

Furosemide is reported as an ingredient of Lasix Retard in the following countries:


  • Austria

  • Sweden

International Drug Name Search

Thursday, April 2, 2009

Tobramicina Normon




Tobramicina Normon may be available in the countries listed below.


Ingredient matches for Tobramicina Normon



Tobramycin

Tobramycin sulfate (a derivative of Tobramycin) is reported as an ingredient of Tobramicina Normon in the following countries:


  • Spain

International Drug Name Search